TickerTalks
Browse all tickers →
TickerTalks›$AMGN
AMAMGN

Amgen Inc.

$AMGN·$222B·Drug Manufacturers - General·Healthcare
$429.94-0.6%YTD+18.6%1Y+51.4%
Mentions · last 7 days
2026-08-21: 22 posts2026-08-22: 11 posts2026-08-23: 13 posts197-1%
Price updated 7m ago·X counts updated 8d ago
AMAMGN
$AMGNAmgen Inc.
$429.95-0.57%197 posts-1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AMGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-30

The move is getting stronger, with heavier trading behind it.

Amgen making S&P 500 all-time highs on Tezspire, MariTide obesity readouts, and the Lp(a) race — cyber incident in the rearview.

Amgen is one of the original biotech giants — Prolia, Enbrel, Repatha — that has quietly rebuilt its growth engine around obesity (MariTide), asthma (Tezspire) and cardiovascular (Lp(a)). It's making all-time highs while the sector debates the GLP-1 wars.

Why the setup works:

  • Operational story is real: Q1 revenue grew 5.8% year-on-year to $8.6B, op margin 31% — mega-pharma actually growing after a decade of Prolia/Enbrel worry.
  • Pipeline is fresh: Tezspire hit primary and all key secondary endpoints in Phase 3 eosinophilic esophagitis (with AZN as partner) — an approved-drug label expansion in a real unmet-need category is the catalyst that reprices a franchise.
  • Valuation is fair: 24x earnings, 13.5x EV/EBITDA, 5.1x sales on 14% ROIC — mid-range for a mega-pharma with active pipeline; room if Lp(a) lands ahead of NVS/LLY.
  • Position confirms breakout: 92nd percentile of the 52-week range, 11% above the 50-day, 21% above the 200-day — 'four horsemen' framing (LLY/MRK/VRTX) is the crowd catching up.
  • Insider signal is mixed: officer Khosla sold ~$1.35M via option exercise-and-sell — distribution at the highs.
  • The July 31 cybersecurity incident (Item 1.05) is one to watch — material PHI exfiltration will produce regulatory activity.

The November 3 print extends the run — reiterated Tezspire timeline and MariTide readout schedule keeps the multiple expanding; a safety signal in obesity or an Lp(a) delay pulls the stock back to the 200-day near $390.

Agrees with X sentimentAgree — the crowd's specific anchors (S&P 500 all-time highs, Tezspire eosinophilic esophagitis positive, Lp(a) race positioning, 'four horsemen' framing with LLY/MRK/VRTX) all map to real signals; the honest add is the cybersecurity incident (Item 1.05, July 31) is worth flagging even though the market has digested it.

What to watch: November 3 earnings — reiterated Tezspire label-expansion timeline and MariTide obesity readout schedule extends the multiple; a specific safety signal in obesity or an Lp(a) delay is the trigger for a pullback to the 200-day near $390.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment14 posts analyzed · as of 2026-08-30

Amgen's thread turns emphatically bullish on Tezspire's Phase 3 win in eosinophilic esophagitis, meeting both co-primary and all key secondary endpoints and turning up heat on Dupixent. Posters also cite a fresh AMGN all-time high, its position as IBB's largest holding (with IBB +46.8% and XBI +76.9% over 12 months), and the whole obesity stack (LLY, AMGN's monthly MariTide, HALO delivery) breaking out together. The lone bearish note is a hypothetical GIP-antagonism CV risk letter around MariTide.

Read the AI verdict + X sentiment for $AMGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops biologics for oncology, cardiovascular, bone health, and inflammation with a growing biosimilar portfolio and obesity pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $AMGN.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $AMGN

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+47.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
24.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
13.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
31.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
4.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
89.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
71.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
6.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$6.29$5.62+11.9%
Q1 2026Apr 30, 2026$5.15$4.77+8.0%
Q4 2025Feb 3, 2026$5.29$4.73+11.8%
Q3 2025Nov 4, 2025$5.64$5.02+12.4%
Next earningsTue, Nov 3·consensus EPS $5.79

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$8.6B+5.8%68.2%30.9%$3.37$1.5B
Q4 FY25$9.9B+8.9%81.9%39.8%$2.47$961.0M
Q3 FY25$9.6B+12.4%67.8%26.4%$5.98$4.2B
Q2 FY25$9.2B+9.3%67.2%28.8%$2.66$1.9B

Forward consensus

5-year forecast · up to 25 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$37.7B$37.3B – $38.2B$22.36$22.01 – $22.6524
FY27$38.7B$37.7B – $40.0B$23.42$22.10 – $24.2522
FY28$39.8B$36.7B – $44.5B$24.42$19.68 – $26.8625
FY29$41.1B$39.7B – $43.5B$25.85$24.71 – $27.8212
FY30$42.7B$41.2B – $45.2B$27.48$26.27 – $29.5812

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.92%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+21.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 538.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.415-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 13Rachna KhoslaSVP, Business Development1.3K sh$521KSellAug 11Rachna KhoslaSVP, Business Development2.0K sh$825KSellAug 6Nancy A. GrygielSVP & CCO1.0K sh$402KSellAug 6Derek MillerSVP, Human Resources1.8K sh$733K
+ 56 other (29 awards · 24 inkinds · 3 exempts) in window

See when $AMGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial eventJul 318-K — Item 1.05
AI summary

Amgen Inc. disclosed a material cybersecurity incident (Item 1.05) in which unauthorized actors exfiltrated data — including proprietary company data and patient protected health information — from cloud environments hosted by third-party providers. Amgen determined the incident is material as of July 29, 2026, activated its incident response plan, and engaged forensic experts. No impact to products, manufacturing, or financial reporting has been identified; the investigation is ongoing and regulatory/legal notification requirements are being assessed. Amgen believes the financial impact is not reasonably likely to be material, but IP and patient data exposure at this scale is a reputational and regulatory risk.

8-KShareholder voteMay 208-K — Item 5.07: Shareholder vote
AI summary

Amgen Inc. (AMGN) disclosed the results of its annual meeting of shareholders in an 8-K filing under Item 5.07. Shareholders voted on an advisory say-on-pay resolution, ratification of the independent auditor, shareholder proposals. All management-sponsored proposals were approved by majority shareholder vote. Annual meeting results are a routine disclosure that confirms shareholder ratification of the board's composition and compensation practices.

8-KOfficer or director changeMay 198-K — Item 5.02: Officer or director change
AI summary

Amgen Inc. (AMGN) filed an 8-K under Item 5.02 disclosing a change in its executive leadership or board composition. The filing reports both a departure and an appointment in Chief Executive Officer. Individuals named in the filing include Amgen Inc, Its Charter. Leadership changes at the C-suite and board level are material events requiring 8-K disclosure within four business days, as they can affect company strategy, investor confidence, and operational continuity.

8-KOfficer or director changeApr 228-K — Item 5.02: Officer or director change
AI summary

AMGN disclosed a personnel change (8-K Item 5.02, dated 2026-04-22). An executive departure and a new appointment are both reported. President and Chief Technology Officer. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 14 other (4 proxys · 3 13Gs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?fool.com·2d agoBlue Edge Capital LLC Purchases New Position in Amgen Inc. $AMGNdefenseworld.net·4d agoAZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Studyzacks.com·4d agoArini Capital Management Ltd Buys Shares of 20,000 Amgen Inc. $AMGNdefenseworld.net·5d agoTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTSprnewswire.com·5d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$PFE$NVO$JNJ$GILD$ABBV$AZN
Voices on X · top 10 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport